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E-mail: christian.buchholz@pei.deSelective gene delivery into subtypes of interneurons remains
an important challenge in vector development. Adeno-associ-
ated virus (AAV) vector particles are especially promising for
intracerebral injections. For cell entry, AAV2 particles are sup-
posed to attach to heparan-sulfate proteoglycans (HSPGs) fol-
lowed by endocytosis via the AAV receptor (AAVR). Here, we
assessed engineered AAV particles deﬁcient in HSPG attach-
ment but competent in recognizing the glutamate receptor 4
(GluA4, also known as GluRD or GRIA4) through a displayed
GluA4-speciﬁc DARPin (designed ankyrin repeat protein).
When injected into the mouse brain, histological evaluation re-
vealed that in various regions, more than 90% of the transduced
cells were interneurons, mainly of the parvalbumin-positive
subtype. Although part of the selectivity was mediated by the
DARPin, the chosen spleen focus-forming virus (SFFV) pro-
moter had contributed as well. Further analysis revealed that
the DARPin mediated selective attachment to GluA4-positive
cells, whereas gene delivery required expression of AAVR.
Our data suggest that cell selectivity of AAV particles can be
modiﬁed rationally and efﬁciently through DARPins, but
expression of the AAV entry receptor remains essential.
INTRODUCTION
Interneurons form a diverse class of neurons that establish inhibitory
circuits in the brain. They have been suggested as crucial players in a
number of brain disorders including schizophrenia, epilepsy, autism,
and intellectual disabilities.1,2 Compared with excitatory neurons,
they are less abundant (about 5-fold) and form synapses preferentially
with local neurons, i.e., neurons of the network that they themselves
reside in. Interneurons are often differentiated into four types
based on the expression of particular proteins: parvalbumin (PV)-ex-
pressing interneurons, a heterogeneous population of somatostatin
(SST)-expressing interneurons, the population of the ionotropic sero-252 Molecular Therapy: Methods & Clinical Development Vol. 14 Septe
This is an open access article under the CC BY-NC-ND license (httptonin receptor 5HT3a (5HT3aR)-expressing interneurons, and
neuron-derived neurotrophic factor-expressing neurons; together,
these subtypes make up the mouse neocortical GABAergic interneu-
ronal population.3 Beyond that, interneurons can be further divided
into several subgroups.4,5 The selective genetic manipulation of
particular interneuronal subtypes is key to developing novel treat-
ment strategies and to improving our understanding about funda-
mental processes in brain function. In mice, this task has been tackled
by the generation of transgenic animals harboring speciﬁc promoter
and enhancer elements that had been found active in distinct inter-
neuronal subtypes. However, other vertebrate species are less
amenable for this approach. Especially in non-human primates,
high maintenance costs, long generation cycles, and ethical concerns
are limiting factors.6,7 Further, the selectivity mediated by these ele-
ments is often impaired or even lost when their size is reduced to
become compatible with the packaging capacity of viral vectors.
This holds especially true for adeno-associated virus (AAV) vector
particles, which are preferred for intracerebral administrations
because of their efﬁcient spreading from the injection site.
Although some progress has been made in targeting neurons in a re-
gion-speciﬁc fashion with viral vectors, restricted gene delivery to
deﬁned neuronal subtypes is still scarce. A single publication
described unmodiﬁed AAV particles derived from the AAV1 serotype
that showed some preference for murine interneurons. This, however,mber 2019 ª 2019 Paul-Ehrlich-Institut.
://creativecommons.org/licenses/by-nc-nd/4.0/).
www.moleculartherapy.orgwas only the case when the particles were injected at a low dose.8
Although this approach has not been pursued by other scientists, it
suggested that at least in principle interneuron targeting with AAVs
may be possible. Important progress has then been made by inserting
genetic elements into the AAV transfer vector. Restricted gene
expression in GABAergic interneurons in various brain regions and
different species was achieved with the enhancer elements of the
distal-less homeobox family Dlx1/2 or Dlx5/6.9,10 In a detargeting
approach, the insertion of a series of microRNA (miRNA) target sites
mediated the selective gene expression in GABAergic interneurons of
the mouse cortex.11
An alternative strategy in targeted gene delivery is to modify the sur-
face of viral vectors such that they attach selectively to the target cell
population.12 The rational approach relies on displaying single-chain
antibodies or designed ankyrin repeat proteins (DARPins) on the par-
ticle surface, thereby achieving attachment to a cell surface marker of
choice with high afﬁnity.13 This approach was initially described for
lentiviral vectors.14 These were pseudotyped with paramyxoviral gly-
coproteins engineered such that usage of the natural entry receptors
was replaced by the targeted surface protein.15 In an attempt to trans-
fer this strategy to AAV vector particles, which are most commonly
used for gene therapies and optogenetic studies, the AAV2 capsid
proteins were mutated in residues R585A and R588A to destroy bind-
ing to heparan-sulfate proteoglycan (HSPG), the primary AAV2
attachment site,16–18 and fused to DARPins recognizing tumor sur-
face antigens.19,20 These AAV particles were highly selective for
tumor cells expressing the targeted antigens even upon systemic
injection into tumor-bearing mice.
In order to apply this approach for a targeted gene delivery into inter-
neurons with AAV, we started out by targeting the glutamate receptor
4 (GluA4), which we had previously found to be expressed preferen-
tially in PV-positive interneurons.21,22 To generate GluA4-speciﬁc
DARPins, we expressed and puriﬁed the extracellular amino-terminal
domain (ATD) of murine GluA4 and used it as bait for several rounds
of selection of a library covering more than 1013 variants of DARPins
by ribosomal display. The ATD of GluA4 differs in only two amino
acid positions betweenmouse, rat, marmoset, and human but exhibits
only up to 62% sequence identity to the other glutamate receptor fam-
ily members GluA1–3. The subsequent analysis of binders revealed
DARPin 2K19 to be most efﬁcient in mediating gene delivery by
AAV into GluA4-expressing Chinese hamster ovary (CHO) cells.
Parental CHO or CHO cells expressing GluA1 or GluA2 were not
or were only minimally transduced, thus conﬁrming the selectivity
of the resulting GluA4-AAV.23
Here, we investigated the gene delivery activity of GluA4-AAV in vivo
upon intracerebral injections into various brain regions. Our analysis
revealed a high preference for interneurons, especially those being
PV-positive. Besides attachment to GluA4, also promoter choice
contributed to this selectivity. Gene transfer studies with cell lines be-
ing deﬁcient for the recently identiﬁed AAV receptor (AAVR; also
named KIAA0319L)24,25 demonstrated the display of 2K19-mediatedMolecular Thecell attachment, whereas AAVR expression was required for func-
tional gene delivery.
RESULTS
To evaluate the cell-type selectivity of GluA4-AAV in vivo, we pack-
aged the reporter gene for the GFP under the control of the spleen
focus-forming virus (SFFV) promoter into the particles, which were
then injected stereotactically into two brain regions, allowing analysis
of gene delivery into the motor cortex, the sensorimotor cortex
(SMC), the retrosplenial granular (RSG) cortex, and the striatum
(Figure 1A). Three weeks after injection, the analysis of consecutive
brain slices revealed that the injected particles had spread from the in-
jection site covering a distance of at least 2.6 mm (Figure 1B). To
determine whether PV+ interneurons had been hit by the particles,
the sections were co-stained for PV and the neuronal marker
NeuN. Strikingly, almost every PV+ cell was GFP+, whereas only a
small fraction of the NeuN+ cells was GFP+ (Figure 1C). This was
valid for all four brain regions that were evaluated (Figure 1D). For
quantiﬁcation of the fraction of PV+ interneurons among the GFP+
cells, we chose a conservative approach taking only those events
into account that were double positive without doubt. Accordingly,
cells that gave signals only marginally above background or did not
show up on at least two consecutive slices were not taken into account
(Figure S1). The obtained average numbers for the different brain re-
gions ranging between 63% and 69% thus represented minimum
values rather underestimating the fraction of PV+/GFP+ interneurons
(Figure 1D). To identify the source of the other GFP+ cells, we stained
against the general interneuron marker GAD67. Almost 90% of the
cells were on average also positive for GAD67, thus conﬁrming the
high selectivity of GluA4-AAV for interneurons (Figure 1E).
In order to assess the contribution of the GluA4-speciﬁc DARPin to
the selectivity for PV+ interneurons, we generated AAV particles
carrying the HSPG mutations but displaying no targeting ligand
(AAVmut). Interestingly, these particles also exhibited some selectivity
for interneurons upon injection into the cortex, indicating that the
observed transduction proﬁle was not solely due to the displayed
GluA4-targeting ligand, but possibly the SFFV promoter used to drive
the yellow ﬂuorescent protein (YFP) reporter as well. To assess this
systematically and in a quantitative way, we put the reporter gene un-
der control of the human synapsin (hSyn) or the CMV promoter and
packaged these constructs into AAVmut particles (Figure S2). These
particles were then injected into the cortex along with GluA4-AAV.
Brain slices were stained for transgene expression, as well as for PV
and the neuronal cell marker NeuN (Figure 2A). Quantiﬁcation of
co-staining with NeuN revealed that the SFFV promoter was equally
neuron speciﬁc as the hSyn promoter (Figure 2B). Both were signiﬁ-
cantly more selective for neuronal cells than the CMV promoter (Fig-
ure 2B). When quantifying PV+ co-staining, the SFFV promoter
mediated indeed a signiﬁcantly more selective YFP expression in
these cells than the hSyn or CMV promoter (Figure 2C). This selec-
tivity was substantially enhanced when the particles were displaying
the GluA4-speciﬁc DARPin (Figure 2C). This analysis revealed that
the SFFV promoter in GluA4-AAV had contributed to its selectivityrapy: Methods & Clinical Development Vol. 14 September 2019 253
Figure 1. Specific In Vivo Transduction of Interneurons with GluA4-AAV
(A) Schematic representation of GluA4-AAV particles and their stereotactic injection into the striatum and motor cortex of 4-week-old C57BL/6 mice. (B–E) Immunofluo-
rescent staining of coronal brain sections from different brain regions 3 weeks after injection of GluA4-AAV-encoding GFP. (B) Representative sections stained with a GFP-
specific antibody from three different cortex regions as depicted in the schematic sagittal plane (lateral 0.60 mm). Reference to bregma is given below the images. Scale bar,
100 mm. (C) Representative section of motor cortex stained with a GFP-specific antibody in combination with an antibody to PV and NeuN. Single-staining andmerge images
are shown. Arrows indicate exemplary cells positive for GFP and PV. Scale bar, 50 mm. (D) Selectivity of GluA4-AAV for PV-positive neurons in different brain regions.
Representative merge images of sections from motor cortex, somatosensory cortex (SMC), retrosplenial granular cortex (RSG), and striatum stained with a GFP-specific
antibody in combination with an antibody to PV (top panel). Scale bar, 100 mm. Amount in percent of GFP and PV double-positive cells from six different mice in the indicated
brain region (bottom panel). For each region andmice, one to five different coronal sections were analyzed. From each section, up to four individual images were counted per
region. One data point represents one image. Mean value and SD are shown. (E) Selectivity of GluA4-AAV for GAD67-positive neurons. Representative section of motor
cortex stained with a GFP-specific antibody in combination with an antibody to GAD67. Single-staining and merge images are shown. Arrows indicate exemplary cells
positive for GFP and GAD67 (left panel). Scale bar, 50 mm. Amount in percent of GFP and GAD67 double-positive cells from six different mice in combined cortex regions
(motor cortex, SMC, and RSG; right panel). For each region and mice, one to five different coronal sections were analyzed. From each section, up to four individual images
were counted per region. One data point represents one image. Mean value and SD are shown.
Molecular Therapy: Methods & Clinical Developmentfor PV+ interneurons, whereas the main effect was mediated by the
DARPin.
We next addressed whether the AAV secondary receptors a5b1 integ-
rin and AAVR were involved in cell entry of GluA4-AAV and thus
gene delivery. Because the capsid residue R513 mediates binding to
a5b1,26 we exchanged this residue against alanine and generated
the corresponding vector particles GluA4-AAVR513A (Figure 3A).
These particles transduced GluA4-positive cells at least as efﬁciently
as GluA4-AAV (Figure 3B), but exhibited an about 4-fold reduced254 Molecular Therapy: Methods & Clinical Development Vol. 14 Septeoff-target activity on GluA4-negative cells (Figure 3C; Figure S3).
Notably, these cell lines were proven to express the integrin a5b1
on their surface (Figure S4A). Capsid mutations can impact assembly
and/or stability of AAV particles. To address this issue, we analyzed
biophysical properties of GluA4-AAVR513A and compared them
with GluA4-AAV and AAV2 particles. Although particle numbers
were similar for the three vector types, both DARPin-displaying par-
ticles contained about two times more empty particles (Figures S5A
and S5B). This is well in line with previous reports about AAVs dis-
playing DARPins with other speciﬁcity.19 Thus, mutating R513 tomber 2019
Figure 2. Contribution of Promoter Usage to
Interneuron Targeting
(A) Immunofluorescent staining of coronal brain sections
from different brain regions 3 weeks after intracerebral in-
jection of targeted (GluA4-AAV) or HSPG-blinded AAV
(AAVmut) vector particles harboring an SFFV, hSyn, or CMV
promoter (GluA4-AAV-SFFV-GFP, AAVmut-SFFV-YFP,
AAVmut-hSyn-YFP, AAVmut-CMV-YFP), respectively. Sin-
gle-staining and merge images of representative sections
of cortex regions stained with a GFP-specific antibody in
combination with an antibody to PV and NeuN are shown.
Scale bar, 50 mm. Schematic drawings of the transgene
cassettes used are provided in Figure S2. (B and C)
Specificity of the indicated AAV vectors toward NeuN-
positive (B) and PV-positive (C) neurons in the cortex.
Percentage of GFP+/PV+ or GFP+/NeuN+ double-positive
cells from at least two different mice, respectively. For each
mouse, two to five different coronal sections were
analyzed. From each section, up to eight individual images
were counted. One data point represents one image. Mean
value and SD are shown. Unpaired t test was performed to
determine significance.
www.moleculartherapy.orgalanine did not impact capsid assembly. Although the thermostability
of GluA4-AAVR513A was slightly reduced compared with its counter-
parts (Figure S5C), temperatures as high as 55C were still tolerated,
indicating that gene delivery with this vector under physiological con-
ditions should proceed unimpaired.
To assess the role of AAVR in the entry of GluA4-AAV, we made use
of the cell line A549, which had been genetically engineered to destroy
AAVR expression.24We equipped the parental and the knockout (ko)
line with GluA4 and veriﬁed the presence of GluA4 and absence of
AAVR by ﬂow cytometry or western blot analysis (Figures S4B and
S4C). The absence of AAVR in knockout cell lines rendered these cells
resistant to transduction, not only by AAV2, but also by GluA4-AAV.
Expression of GluA4 did not change this picture (Figure 3D). Howev-
er, the attachment of GluA4-AAV to GluA4-positive cells was equally
efﬁcient independently of whether these cells expressed AAVR or not
(Figure 3E). Control AAV particles displaying a Her2/neu-speciﬁc
DARPin did not bind to these cells (Figure 3E). Thus, GluA4-AAV
used GluA4 as its primary attachment site on these cells. This was
conﬁrmed in experiments employing HT1080 and HT1080-GluA4Molecular Therapy: Methods & Clincells (Figure 3E), implying that AAVR was not
involved in binding but rather mediated internal-
ization and trafﬁcking of GluA4-AAV.
DISCUSSION
Here we provide proof-of-principle that surface
engineering and attachment of vector particles
to GluA4 result in selective gene delivery to inter-
neurons. This is to our knowledge the ﬁrst
description of applying a rational design-based
surface engineering strategy for interneuron tar-geting with AAV vectors. Especially PV+ interneurons were hit by
GluA4-AAV, which is well in agreement with several independent
studies conﬁrming that GluA4 protein and mRNA are selectively up-
regulated in PV+ interneurons.22,27–29 The selectivity of GluA4-AAV
for interneurons appears to be well in the range of that observed with
AAVs targeted to interneurons via enhancer9 or miRNA11 targeting
strategies. Notably, both can be easily combined with GluA4-AAV
by inserting these elements into the transfer vector plasmid. PV+ in-
terneurons are central to the maintenance of an excitation-inhibition
balance and to the generation of gamma-band rhythms, thereby play-
ing an important role in several psychiatric diseases.4,30,31 Thus, a
dysfunction of PV+ interneurons leads to de-synchronization of
neuronal circuits in the brain and ultimately to behavioral deﬁcits.32
Accordingly, GluA4-AAV can be regarded as a novel instrumental
tool for studies into the pathogenicity and therapy of these disorders.
To characterize the entry properties of GluA4-AAV, we made use of
information and tools available for the AAV secondary receptors
a5b1 integrin and AAVR. Our data are in line with the view that
a5b1 integrin serves as an attachment, but not as an entry receptor,ical Development Vol. 14 September 2019 255
Figure 3. AAVR Is Essential for Entry of GluA4-AAV
(A) Model of a GluA4-AAVR513A vector particle is shown. DARPins (red) are extruding from pores at the 5-fold symmetry axis of the AAV capsid (left). Point mutations inserted in
the capsid are shown in red and orange on the blow-up of the 3-fold axis (right). The illustration was created using Pymol. Adapted fromMu¨nch and colleagues.19 (B) GluA4-
targeted vectors harboring two (R585A and R588A; GluA4-AAV) or three point mutations (R585A, R588A, and R513A; GluA4-AAVR513A) transduce GluA4-positive CHO-
GluA4 cells. Cells were incubated with the indicated AAV vectors encoding GFP at a GOI of 1.25 106 (GluA4-AAV, GluA4-AAVR531A) or 1 104 (AAV2). Cells were analyzed
72 h after transduction by flow cytometry. Untransduced cells were used as control. (C) Reduced off-target transduction with GluA4-AAVR513A. GluA4-positive or -negative
cells of the indicated cell lines were incubated with GluA4-AAVmut or GluA4-AAVmut
R513A vectors encoding GFP at a GOI of 7.9  105 (CHO) or 2.6  105 (SH-SY5Y and
HT1080). Cells were analyzed 72 h after transduction by flow cytometry. Each transduction experiment was performed in technical triplicates. The mean and SD are shown.
****p% 0.0001; ***p% 0.001; **p% 0.01; *p% 0.05. ns, not significant by unpaired t test. Representative dot plots are shown in Figure S3. (D) AAV vectors transduce AAVR-
positive cell lines only. AAVR-positive and -negative cell lines were incubated with the indicated vector stocks encoding GFP at a GOI of 4.9  105 (GluA4-AAV, GluA4-
AAVR531A, Her2-AAV) or 1 104 (AAV2). Cells were analyzed 72 h after transduction by flow cytometry. Each transduction experiment was performed in technical triplicates.
Mean value and SD are shown. (E) GluA4-AAV vector particles bind to AAVR-positive and -negative GluA4-expressing cells. The indicated cell lines were incubated with
GluA4-AAVR513A at a GOI of 3  104 for 1 h at 4C. Bound particles were stained with an AAV capsid-specific antibody in combination with a PE-conjugated secondary
antibody. Mean PE fluorescence intensity (MFI) was measured via flow cytometry. An unrelated vector targeted to Her2 (Her2-AAV; GOI 8 104) was used as control. Each
binding experiment was performed in technical triplicates. Mean value and SD are shown. ***p% 0.001. ns, not significant by unpaired t test.
Molecular Therapy: Methods & Clinical Developmentbecause GluA4 particles, in which the contact residue R513 was
mutated, were unaffected in gene delivery to GluA4-positive cells,
but exhibited reduced off-target activity on GluA4-negative cells.
Much stronger effects were caused by the presence or absence of
AAVR on target cells. Although GluA4-AAV bound efﬁciently to
AAVR-deﬁcient cells via the displayed DARPin, gene transfer, and
thus functional particle entry, was not detectable.
This strict dependency of GluA4-AAV on the presence of AAVR has
multiple consequences and raises important questions for the cell en-
try mode of capsid engineered AAVs in general. First, GluA4-AAV
can deliver genes to AAVR+ cells only. Although the high afﬁnity
of the DARPin attaches the particles preferentially to GluA4+ cells,
only those cells that are also AAVR+ can express the transferred
gene. Thus, GluA4 serves as attachment receptor, but not as
entry receptor for GluA4-AAV. GluA4 thus replaces HSPG but
cannot overcome the dependency on AAVR (Figure 4). Our data
suggest that binding of AAV to AAVR has essential roles in AAV en-
try beyond cell attachment. Analogous to other well-characterized256 Molecular Therapy: Methods & Clinical Development Vol. 14 Septefunctional virus receptors, these roles could be triggering of endocy-
tosis, facilitating intracellular trafﬁcking, or inducing a conforma-
tional change in the viral particle to enable crossing of the endosomal
membrane.24,33 Second, AAV particles deﬁcient in both HSPG
and GluA4 binding still can deliver genes upon intracerebral
injection. From our data, it cannot be distinguished whether these
particles used another attachment receptor ﬁrst or contacted
AAVR immediately. Especially in a tissue as densely packed with cells
as brain, the latter scenario may be a possibility. Histological data
about the AAVR expression pattern in mouse and human brain
will be instrumental to better predict and understand the bio-
distribution of these particles and of GluA4-AAV upon intracerebral
injection.
Receptor-targeted AAVs thus differ principally from their lentiviral
vector-based counterparts, because the latter can be targeted to their
actual entry receptor.34 Although the current study focuses on
GluA4-AAV, it is likely that also other receptor-targeted AAVs dis-
playing DARPins, like Her2-AAV, epithelial cell adhesion moleculember 2019
Figure 4. Model for the Surface Proteins Involved in Entry of GluA4-AAV
(A) Cell entry of AAV2. Cooperative binding of AAV particles to the primary attachment receptor HSPG and possibly also integrin a5b1 mediates contact to AAVR, which then
leads to internalization and trafficking through the cytoplasm. (B) GluA4-AAV does not bind to HSPG because of the introduced capsid mutations (R585A and R588A;
depicted as red crosses). Primary cell binding is mediated by the GluA4-receptor via the displayed DARPin. Afterward, cooperative binding to AAVR takes place leading to
internalization and trafficking through the cytoplasm.
www.moleculartherapy.org(EpCAM)-AAV, and CD4-AAV, rely on AAVR expression in their
entry modes. Beyond that, it will be important to address this issue
also for capsid-engineered AAVs selected from AAV libraries. With
the AAV2 capsid residues being in contact with AAVR having
recently become available,35 it will now be possible to clarify whether
AAVs can be engineered such that AAVR usage can be replaced by
cell surface receptors of choice.
MATERIALS AND METHODS
Plasmid Constructions
For generation of AAV transfer vector plasmids encoding the YFP
under the control of either the promoter from the SFFV, the promoter
of hSyn or the promoter of the cytomegalovirus (CMV) (Figure S2),
we ﬁrst exchanged the mouse APPsa coding sequence under the
control of the hSyn promoter in pssAAV-hSyn-APPsa36 via BamHI
and HindIII restriction cloning resulting in pssAAV-hSyn-eYFP
(enhanced YFP). Afterward, the hSyn promoter was replaced by the
SFFV promoter via PCR ampliﬁcation (primers 2298 and 2723, tem-
plate pSEW23) and subsequent restriction cloning with MulI and
BamHI generating pssAAV-SFFV-eYFP. The CMV promoter was
directly derived from pcDNA3.1(+) and inserted into pssAAV-
hSyn-eYFP using the restriction sites MulI and BamHI, resulting in
pssAAV-CMV-eYFP.
The AAV2 capsid residue R513 was mutated to alanine in the plasmid
pRCVP2koA, encoding the rep and the mutated cap proteins of
AAV-2 deﬁcient for HSPG binding (R585A and R588A) and carrying
a mutated VP2 start codon,19 and in pGluA4.2K19-VP2 encoding the
GluA4 DARPin 2K19 in fusion with HSPG-blinded VP2 protein.23 In
brief, a part of the coding sequences rep (primers 2195, 2198, 2199,
and 2202) was ampliﬁed by overlapping size extension PCR intro-Molecular Theducing point mutation R513A. The generated fragment was
inserted into pRCVP2koA and pGluA4.2K19-VP2 by sticky end liga-
tion via the restriction sites BsiWI/XcmI, respectively, resulting in
pRCVP2koA-R513A and pGluA4.2K19-VP2-R513A. All primer
sequences for plasmid construction are provided in Table S1.
Cultivation and Generation of Cell Lines
HEK293T (ATCC CRL-11268), CHO-K1 (ATCC CCL-61), HT1080
(ATCC CCL-121), and A549 (ATCC CCL-185) cells were cultivated
in DMEM (Sigma-Aldrich, Munich, Germany) supplemented with
10% fetal calf serum (FCS; Biochrom, Berlin, Germany) and 2 mM
L-glutamine (Sigma-Aldrich, Munich, Germany). SH-SY5Y (ATCC
CRL-2266) cells were cultivated in DMEM/F-12 Nutrient Mixture
(Ratio 1:1; Thermo Fisher Scientiﬁc, Darmstadt, Germany) supple-
mented with 10% FCS and 2 mM L-glutamine. The cell lines CHO-
GluA4 and HT1080-GluA4 were derived from CHO-K1 and HT1080
cells by lentiviral transduction, respectively,15,23 and cultivated in the
samemedium in presence of 10mg/mL puromycin (Thermo Fisher Sci-
entiﬁc, Darmstadt, Germany). A549AAVRko cells were derived from
A549 cells by CRISPR-Cas9 technology24 and cultivated in the same
medium. SH-SY5Y-GluA4 cells, A549-GluA4 cells, and A549AAVRko-
GluA4 were established by lentiviral transduction of the respective
parental cell line with lentiviral particles having packaged the coding
sequence for GluA4 with an N-terminal myc tag.15 Transduced cells
were selected and cultured in media containing 2.5 mg/mL (A549-
GluA4, A549AAVRko-GluA4) or 10 mg/mL (SH-SY5Y-GluA4) puromy-
cin. Transgene expression was veriﬁed via ﬂow cytometry analysis.
AAV Vector Production
GluA4-AAV and AAV2 vector particles were generated using the
adenovirus-helper-free AAV-packaging strategy as described beforerapy: Methods & Clinical Development Vol. 14 September 2019 257
Molecular Therapy: Methods & Clinical Developmentusing polyethylenimine (PEI).20,37 In brief, 24 h prior to transfection,
2  107 HEK293T cells were seeded per T175 ﬂask. On the day of
transfection, the cell culture medium was replaced by 10 mL
DMEM with 15% FCS and 2 mM L-glutamine (DMEM+FCS). For
the transfection mix, 35 mg of total DNA was mixed with 2.3 mL of
DMEMwithout additives and added to 2.2 mLDMEM supplemented
with 140 mL of 18 mM PEI solution. After incubation for 20 min at
room temperature, the transfection mix was added to the HEK293T
cells. Forty-eight hours after transfection, cells were scraped off, pel-
leted (400 g, 10 min, 4C), and lysed using Tris-HCl NaCl (pH 8.5).
After three freeze and thaw cycles in liquid nitrogen, cells were treated
with Benzonase (50 U/mL cell lysate; Sigma-Aldrich, Hamburg, Ger-
many) for 30 min at 37C. The cleared lysates (3,700  g, 20 min,
4C) were puriﬁed by iodixanol gradient puriﬁcation for 2 h at
290,000  g in a Beckman 70Ti rotor, and AAV particles were har-
vested from the 40% iodixanol layer. For production of AAV2,
HEK293T cells were transfected with plasmids pXX6-80,37 pRC,38
and the self-complementary transfer vector pscAAV-SFFV-GFP.20
For production of targeted AAVmut or AAVmut
R531A vectors, the
plasmid pRC was substituted by plasmid pRCVP2koA and pDAR-
Pin-VP2 (AAVmut) or pRCVP2koA-R513A and pDARPin-VP2-
R531A (AAVmut
R531A). For the production of non-targeted AAVmut
vectors encoding YFP under the control of the SFFV, hSyn, or
CMV promoter, the plasmids pXX6-80 and pRCVP2koA and one
of the following single-stranded transfer vector plasmids were used:
pssAAV-SFFV-eYFP, pssAAV-hSyn-eYFP, or pssAAV-CMV-eYFP.
Plasmid ratios for the generation of AAV vectors are provided in
Table S2. Genomic AAV vector titers were determined via free in-
verted terminal repeat (ITR)-speciﬁc qPCR as described before.39
Transduction of Cell Lines and Flow Cytometry Analysis
For transduction, 0.8–2.0  104 cells of indicated cell lines were
seeded into a single well of a 96-well plate. Twenty-four hours later,
the cell culture medium was exchanged by 50 mL AAV vector stock
per well at a given genomic particle of infection (GOI). After 2 h,
150 mL cell culture medium was added per well. At day 3 post trans-
duction, transduced cells were determined by ﬂow cytometry analysis
based on the indicated percentage of green ﬂuorescent cells. Flow cy-
tometry analysis was performed on the MACSQuant Analyzer 10
(Miltenyi Biotec, Bergisch Gladbach, Germany). Data were analyzed
using FCS Express version 4.0 (DeNovo Software).
AAV Cell Binding Assay
A total of 5  104 cells were incubated with 1.5  109 particles of
GluA4-AAVmut
R513A or Her2-AAVmut for 1 h at 4C. Afterwards,
cells were washed twice with washing buffer (PBS, 2% FCS, 0.1%
NaN3). Bound particles were subsequently stained by incubation of
cells with an anti-AAV2 intact particle antibody (clone A20, diluted
1:20; Progen, Heidelberg, Germany) and a PE-conjugated anti-
mouse antibody (diluted 1:50; Miltenyi Biotec, Bergisch-Gladbach,
Germany). After each antibody incubation step, cells were washed
twice with washing buffer. Bound vector particles were measured
by ﬂow cytometry analysis (MACSQuant Analyzer 10; Miltenyi
Biotec, Bergisch Gladbach, Germany) detectingmean PE ﬂuorescence258 Molecular Therapy: Methods & Clinical Development Vol. 14 Septeintensity. Data were analyzed using FCS Express version 4.0 (DeNovo
Software).
Intracerebral Injection of AAV Vectors
Stereotactic delivery of AAV vectors into the brain of mice has been
approved by the responsible authorities. Injections into the cortex (co-
ordinates: 0.5 mm anterior, 1.8 mm lateral, and 1.0–2.0 mm ventral to
bregma) and striatum (coordinates: 0.5 mm anterior, 1.7 mm lateral,
and 3.0–4.0 mm ventral to bregma) were performed in 4-week-old
C57BL/6 mice as described previously.40,41 Brains of mice were
analyzed 3 weeks after intracerebral injection of AAV vectors.
Immunostainings and Microscopy
For immunohistochemistry after intracerebral injections, mice were
transcardially perfused with 4% PFA in PBS. Brains were embedded
in 4% agar in PBS and cut into 50- to 70-mm-thick coronal sections
(Leica VT1200S vibratome). The sections were blocked and permea-
bilized either in 0.4% Triton X-100, 5% donkey serum, PBS (PV stain-
ing) or 0.05% Triton X-100, 5% donkey serum, and PBS (GAD67
staining) for 30–60 min at room temperature under slight agitation.
Brain slices were stained with a primary antibody cocktail consisting
of a chicken antibody to EGFP (1:1,000; Abcam), a guinea pig anti-
body to NeuN (1:1,000; Millipore), and a rabbit antibody to parvalbu-
min (1:1,000; Sigma) or a mouse antibody to GAD67 (1:500; Milli-
pore) overnight at 4C under slight agitation. On the next day,
slices were washed three times with PBS, before being incubated
with a secondary antibody cocktail consisting of an Alexa 488-conju-
gated anti-chicken antibody (1:250; Invitrogen), an Alexa 647-conju-
gated anti-guinea pig antibody (1:1,000; Invitrogen), and an Alexa
594-conjugated anti-rabbit antibody (1:250; Jackson) or an Alexa
594-conjugated anti-mouse antibody (1:1,000; Invitrogen) for 2–3 h
at room temperature and slight agitation. Antibody cocktails were
either prepared in 0.2% Triton X-100, PBS (PV staining), or PBS
only (GAD67 staining). Brain slices were washed twice with PBS
and mounted on coverslips. Slices were analyzed using a laser scan-
ning ﬂuorescence microscope (Zeiss). Images were acquired with an
Optronics Magnaﬁre Camera using Zeiss Zen software and a 16
(Uplan apo) objective lens. Image analysis was performed using Zeiss
Zen software. Cell counting was performed using Cell Proﬁler
software.
Statistical Analysis
Statistical analyses were performed with Prism 7 software (Graph-
Pad). Tests for statistical signiﬁcance used the unpaired two-tailed
Student’s t test as indicated; p values less than 0.05 were considered
signiﬁcant.
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